https://www.selleckchem.com/products/incb054329.html Hypertrophic scar is a common skin fibrosis disease. Currently, surgical resection, drug injection and radiotherapy were often used for treating it; however, limitations or adverse reactions still exist in these treatment. With the deepening understanding of immune response and related cytokines in the process of hypertrophic scar formation, the immunotherapy for hypertrophic scar is also gradually improved. Interleukin 10 (IL-10) is an important member of the leukocyte family, which has different expression in different cells and exerts an immunosuppressive effect mainly through regulating the activity of immune cells infiltrated in hypertrophic scar. However, in some cases, IL-10 also exhibits an immunostimulatory effect. Therefore, its role in the formation of hypertrophic scar is critical for developing and improving the immunotherapy for hypertrophic scar.Objective To express the recombinant HCV NS2, establish and evaluate the detection method of serum anti-ns2 antibody based on chemiluminescence. Methods Using the NS2 sequence plasmid of HCV 1b genotype (PUC-NS2) as the template, a recombinant plasmid containing the whole NS2 sequence (pGEX-KG-NS2) was constructed. Prokaryotic expression of NS2 protein was induced. The purified NS2 fusion protein was coated on the microplate, and the anti-NS2 antibody detection kit was prepared based on chemiluminescence, and the methodological index was evaluated. Results NS2 fusion protein with relative molecular weight (Mr) of about 51 000 was successfully induced and expressed, and a serum anti-NS2 antibody detection kit was synthesized. Methodological evaluation of kit Precision test showed favorable results (intra batch coefficient of variation [CV] was 4.60%~9.17%, inter batch CV was 6.62%~10.09%). The relative luminous intensity ratio (RLIR) of the blank limit and the detection limit were 1.57 and 4.80 (r=0.9870), respectively, and the analytical measurement range (A